U.S. markets open in 1 hour 41 minutes
  • S&P Futures

    4,273.00
    -34.75 (-0.81%)
     
  • Dow Futures

    33,910.00
    -208.00 (-0.61%)
     
  • Nasdaq Futures

    13,529.00
    -129.25 (-0.95%)
     
  • Russell 2000 Futures

    2,005.30
    -18.00 (-0.89%)
     
  • Crude Oil

    86.44
    -0.09 (-0.10%)
     
  • Gold

    1,783.30
    -6.40 (-0.36%)
     
  • Silver

    19.76
    -0.32 (-1.59%)
     
  • EUR/USD

    1.0166
    -0.0005 (-0.05%)
     
  • 10-Yr Bond

    2.8240
    0.0000 (0.00%)
     
  • Vix

    20.49
    +0.54 (+2.71%)
     
  • GBP/USD

    1.2064
    -0.0030 (-0.25%)
     
  • USD/JPY

    135.1410
    +0.9260 (+0.69%)
     
  • BTC-USD

    23,754.08
    -297.34 (-1.24%)
     
  • CMC Crypto 200

    565.98
    -5.93 (-1.04%)
     
  • FTSE 100

    7,506.88
    -29.18 (-0.39%)
     
  • Nikkei 225

    29,222.77
    +353.86 (+1.23%)
     

Ultragenyx Shares Tumble On Initial Efficacy Missing Expectations, This Analyst Sees 'Viable Path Forward"

·1 min read
  • Earlier today, Ultragenyx Pharmaceutical Inc (NASDAQ: RARE) released updated interim GTX-102 data, including Day 128 assessments from 9 patients.

  • The Overall CGI-C-AS score improved by 1 point in 5/6 patients (average 0.8) in Cohort 4 and 1 point in 2/3 patients (average 0.7) in Cohort 5.

  • Credit Suisse says that the result is slightly lower than Street expectations.

  • But the physicians' CS spoke to highlighted a very low bar for a clinically meaningful product, and higher loading doses/longer dosing period could potentially improve these initial results.

  • Additional efficacy metrics presented were supportive of clinical improvements.

  • The most common AE was vomiting, which may be related to the procedure and anesthesia.

  • Data from the U.S. cohort that was dosed at 2 mg showed a 2-point overall improvement in two evaluable patients. The ex-US study protocol is now amended to enroll two additional cohorts sequentially, Cohort 6 (younger, starting at 7.5 mg loading doses) and Cohort 7 (older, starting at 10 mg).

  • Management noted that higher loading doses could significantly improve the efficacy profile.

  • Price Action: RARE shares are down 13.70% at $52.66 during the market session on the last check Tuesday.

Latest Ratings for RARE

Date

Firm

Action

From

To

Feb 2022

Morgan Stanley

Maintains

Overweight

Feb 2022

JP Morgan

Upgrades

Neutral

Overweight

Feb 2022

Morgan Stanley

Maintains

Overweight

View More Analyst Ratings for RARE

View the Latest Analyst Ratings

See more from Benzinga

Don't miss real-time alerts on your stocks - join Benzinga Pro for free! Try the tool that will help you invest smarter, faster, and better.

© 2022 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.